Rasmussen, Torben Riis
Gouliaev, Anja
Jakobsen, Erik
Hjorthaug, Karin
Larsen, Lene Unmack
Meldgaard, Peter
Thygesen, Jesper
Bibi, Rana
Møller, Lars B.
Arshad, Arman
Folkersen, Birgitte
Højsgaard, Anette
Saghir, Zaigham
Larsen, Klaus R.
Ravn, Jesper
Funding for this research was provided by:
AstraZeneca Nordic (ESR-20-20696)
Article History
Received: 23 April 2024
Accepted: 11 November 2024
First Online: 18 November 2024
Declarations
:
: Not applicable. The study is based on fictitious case stories and associated imaging used in the study are fully and irrevocably anonymized. The Danish National Medical Research Ethics Committee () waived the need for ethical approval and referred to the local Institutional Review Board at Aarhus University Hospital (IRB-AUH) for permission to access selected imaging for full and irrevocable anonymization and subsequent use in the study, for which permission was granted. The need for consent to participate was waived by IRB-AUH as it was deemed unnecessary for the intended use according to Danish national regulations (Danish Health Act, § 42 d ()). The use of fictitious case stories and fully and irrevocable anonymized data for research are permissible under Danish and European General Data Protection Regulation (the GPDR rules – REGULATION (EU) 2016/679 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 April 2016, article 26 ()).
: Not applicable. The study is based on fictitious case stories and fully and irrevocably anonymized images, the use of which is permissible under Danish and European GDPR rules as stated and explained above for ‘Ethics approval and consent to participate’.
: The authors declare no competing interests.
: Each author is a senior consultant with extensive experience in lung cancer diagnostics at university hospitals or is conducting research into the function of MDT in lung cancer.